

MDM2-recruiting PROTAC Offers Superior, Synergistic Anti-proliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53

John Hines¹, Schan Lartigue¹, Hanqing Dong², Yimin Qian² and Craig M. Crews^{1,3,4}

¹Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut 06520; ²Arvinas, LLC, New Haven, Connecticut 06511; ³Department of Chemistry, Yale University, New Haven, Connecticut 06520; ⁴Department of Pharmacology, Yale University, New Haven, Connecticut 06520

Supplementary Data File – Table S1

compound concentration (μM)	mean % inhibition by JQ1	E _J	mean % inhibition by idasanutlin	E _N	mean % inhibition by A1874	E _A	CI
0.01	0.4 %	0.004	12.2 %	0.122	2.4 %	0.024	5.20
0.025	0.0 %	0.000	16.2 %	0.162	0.7 %	0.007	23.1
0.10	7.9 %	0.079	37.7 %	0.377	9.2 %	0.092	4.60
0.25	3.6 %	0.036	47.7 %	0.477	53.7 %	0.537	0.92
1.00	7.2 %	0.072	59.1 %	0.591	96.5 %	0.965	0.64
2.50	9.0 %	0.090	60.6 %	0.606	98.6 %	0.986	0.65
10.0	15.1 %	0.151	64.4 %	0.644	96.8 %	0.968	0.72

Supplementary Table S1: Bliss Independence analysis of A1874 activities in A375 cells

The percentage cell inhibition (compared to vehicle-treated control cells) for each compound at each concentration from Figure 3B was converted to their decimal equivalents (E_J for JQ1; E_N for idasanutlin; E_A for A1874) and the Combination Index (CI) value was derived as explained in the Experimental Methods. CI values <1 indicate synergy.